A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorOno Pharmaceutical Co., Ltd.
About this trial
This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.
Eligibility criteria
Qualifiers
Participants with histologically or cytologically confirmed unresectable advanced or recurrent solid tumors.
Participants who are refractory or intolerant to standard therapy.
Participants with a tumor type for which anti-PD-(L)1 antibodies have been approved and who have previously treated with anti-PD-(L)1 antibody containing regimen.
Participants with Eastern Cooperative Oncology Group Performance Status 0 or 1.
Disqualifiers
Participants with a complication or history of severe hypersensitivity to any other antibody drugs.
Participants with concurrent autoimmune disease or a history of chronic or recurrent autoimmune disease
Participants with severe peritoneal dissemination.
Participants with pericardial fluid, pleural effusion, or ascites requiring treatment.
Trial design
Treatments tested in this trial
- ONO-7428
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov